https://www.sifact.it/wp-content/uploads/2019/12/logo_sifact_0-300x111.png
0
0
Segreteria SIFaCT
https://www.sifact.it/wp-content/uploads/2019/12/logo_sifact_0-300x111.png
Segreteria SIFaCT2021-03-10 11:58:432021-03-10 15:02:07SARS-COV-2 pandemic: establishing three risk levels for 19 Italian regions and two autonomous provinces.
https://www.sifact.it/wp-content/uploads/2019/12/logo_sifact_0-300x111.png
0
0
Segreteria SIFaCT
https://www.sifact.it/wp-content/uploads/2019/12/logo_sifact_0-300x111.png
Segreteria SIFaCT2021-03-10 11:52:392021-03-10 15:01:40Restricted mean survival time in advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
https://www.sifact.it/wp-content/uploads/2019/12/logo_sifact_0-300x111.png
0
0
Marco Chiumente
https://www.sifact.it/wp-content/uploads/2019/12/logo_sifact_0-300x111.png
Marco Chiumente2021-02-22 12:26:182022-02-03 12:12:16Vaccini anti Covid-19 Sifact e Assobiotec: dalla preclinica alla real world evidence
https://www.sifact.it/wp-content/uploads/2020/09/sclerosi-multipla.jpg
300
620
Segreteria SIFaCT
https://www.sifact.it/wp-content/uploads/2019/12/logo_sifact_0-300x111.png
Segreteria SIFaCT2020-12-31 11:47:242020-12-31 11:47:27Bollettino SIFACT Insight Gennaio 2021
https://www.sifact.it/wp-content/uploads/2019/12/logo_sifact_0-300x111.png
0
0
Segreteria SIFaCT
https://www.sifact.it/wp-content/uploads/2019/12/logo_sifact_0-300x111.png
Segreteria SIFaCT2020-12-10 16:56:312020-12-10 16:57:28Chimeric antigen receptor T-cell (CART) therapy in non-Hodgkin’s lymphoma: the survival gain improves as more mature follow-up data become available.
https://www.sifact.it/wp-content/uploads/2019/12/logo_sifact_0-300x111.png
0
0
Marco Chiumente
https://www.sifact.it/wp-content/uploads/2019/12/logo_sifact_0-300x111.png
Marco Chiumente2020-12-09 17:22:062020-12-09 17:24:46Covid. Un metodo alternativo per stabilire i livelli di rischio regionali